BioXell announces positive Phase IIb results for Elocalcitol in Benign Prostatic Hyperplasia
Primary endpoint met - Elocalcitol highly effective in arresting prostate growth
15-Oct-2007 -
BioXell S.p.A. announced top-line results of its Phase IIb trial of Elocalcitol in Benign Prostatic Hyperplasia (BPH). The primary endpoint was met with a high degree of statistical significance, with Elocalcitol effectively arresting prostate growth. Elocalcitol also showed relevant effects on ...
benign prostatic hyperplasia
benign prostatic hypertrophy
flow
+5